Category Business

Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate

Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate Merck, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui). The partnership includes an…

Read MoreMerck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the…

Read MoreGilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

TOGETHER FOR CHANGE GENOMICS AND EQUITY INITIATIVE LAUNCHED BY A COALITION OF MEHARRY MEDICAL COLLEGE, REGENERON GENETICS CENTER, ASTRAZENECA, NOVO NORDISK, AND ROCHE TO IMPROVE HEALTH OUTCOMES FOR PEOPLE OF AFRICAN ANCESTRY

TOGETHER FOR CHANGE GENOMICS AND EQUITY INITIATIVE LAUNCHED BY A COALITION OF MEHARRY MEDICAL COLLEGE, REGENERON GENETICS CENTER, ASTRAZENECA, NOVO NORDISK, AND ROCHE TO IMPROVE HEALTH OUTCOMES FOR PEOPLE OF AFRICAN ANCESTRY NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE…

Read MoreTOGETHER FOR CHANGE GENOMICS AND EQUITY INITIATIVE LAUNCHED BY A COALITION OF MEHARRY MEDICAL COLLEGE, REGENERON GENETICS CENTER, ASTRAZENECA, NOVO NORDISK, AND ROCHE TO IMPROVE HEALTH OUTCOMES FOR PEOPLE OF AFRICAN ANCESTRY

Promega to Develop Microsatellite Instability (MSI) Companion Diagnostic IVD Kit in Collaboration With GSK

Promega to Develop Microsatellite Instability (MSI) Companion Diagnostic IVD Kit in Collaboration With GSK –Promega Corporation today announced it plans to develop and commercialize a microsatellite instability (MSI) companion diagnostic (CDx) IVD kit with GSK to identify adult cancer patients with…

Read MorePromega to Develop Microsatellite Instability (MSI) Companion Diagnostic IVD Kit in Collaboration With GSK

Rockwell Medical Enters into 3-Year Product Purchase Agreement with Centers for Dialysis Care

Rockwell Medical Enters into 3-Year Product Purchase Agreement with Centers for Dialysis Care Rockwell Medical, Inc. (the “Company”) (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that…

Read MoreRockwell Medical Enters into 3-Year Product Purchase Agreement with Centers for Dialysis Care

Automata Technologies: $40m fundraise backed by Dimension and A.P. Moller Holding, to expand growing life science lab automation offering

Automata Technologies: $40m fundraise backed by Dimension and A.P. Moller Holding, to expand growing life science lab automation offering –Automata Technologies, a leading automation company powering life sciences labs, has raised $40m to accelerate its rapid growth and industry presence across…

Read MoreAutomata Technologies: $40m fundraise backed by Dimension and A.P. Moller Holding, to expand growing life science lab automation offering

Thought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet

Thought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet The Zayed Prize for Sustainable Development, the UAE’s pioneering prize for sustainable and humanitarian development, held its second forum in…

Read MoreThought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Ligand Pharmaceuticals Incorporated announced that its partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ), (“Jazz”) has been…

Read MoreLigand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai…

Read MoreMerck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator

Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH…

Read MoreVividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator

AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment

AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment Powering AstraZeneca’s transition to net zero, the Company has agreed a 15-year partnership with Future Biogas to establish the UK’s first unsubsidised industrial-scale supply of biomethane gas, and is…

Read MoreAstraZeneca advances UK clean heat and energy efficiencies with £100m commitment